CORE E: TRANSGENIC CORE

JHU-UMD DRC的转基因和ES细胞核心将使约翰·霍普金斯大学的成员 和马里兰大学在老鼠身上高效地产生转基因和基因敲除。弗雷德里克·E。 医学博士Wondisford将担任董事，医学博士Sally Radovick将担任联席董事。两者都是高度 有资格指导这一核心并直接参与糖尿病和糖尿病相关研究的人应该 进一步加强对JHU-UMD调查人员的转基因/基因敲除服务。该中心将利用现有的 约翰霍普金斯大学医学院的转基因核心，增加了专门的技术 支持以较低的成本加快为DRC成员生成鼠标模型。刚果民主共和国将 继续使用高度可靠和高效的协议生成有针对性的ES细胞。智力方面 与产生转基因和敲除/敲入结构和必要的试剂有关 对于许多研究人员来说，ES细胞的产生已经被证明是重要的。通过集中经验和 在这一核心设施方面的专业知识，核心将显著加快中心的发现进度 调查人员。转基因服务将位于JHU空间，该空间已分配给现有 设施，而且这个设施有足够的设备。ES小区服务将位于已连接的CMSC中 大楼，毗邻Wondisford博士的实验室，占地500平方米。英国《金融时报》空间的力量。旺迪斯福德博士和拉多维克博士将 协助设计靶向结构。核心将由Sidhaye博士管理，他将监督 将构建物引入ES细胞，鉴定经历了同源克隆的ES克隆 与各自研究人员的实验室进行重组，并准备注射到 胚泡。促进转基因小鼠从JHU到UMD的转移一直是Core的一部分 功能。或者，核心预算是为UMD制造的MICE在JHU的短期住房成本 成员，如果他们的研究方案需要进行成像或代谢研究。

The Transgenic and ES Cell Core of the JHU-UMD DRC will enable Members at Johns Hopkins University and the University of Maryland to efficiently generate transgenic and knock-out/in mice. Fredric E. Wondisford, M.D. will serve as Director, and Sally Radovick, M.D. will serve as Co-Director. Both are highly qualified to direct this core and their direct involvement in diabetes and diabetes-related research should further enhance transgenic/knock-out services to JHU-UMD investigators. The Center will utilize the existing Transgenic Core at Johns Hopkins University School of Medicine with the addition of dedicated technical support to expedite generation of mouse models for DRC Members and at a lesser cost. The DRC will continue to generate targeted ES cells using highly reliable and efficient protocols. The intellectual aspects associated with the generation of transgenic and knock-out/knock-in constructs and the reagents necessary for ES cells generation have proved to important for many investigators. By concentrating experience and expertise in this Core facility, the Core will markedly accelerate the progress of discovery for Center investigators. Transgenic services will be located in JHU space that is already allocated to the existing facility, and this facility has adequate equipment. ES cell services will be located in the connected CMSC building, adjacent to Dr. Wondisford's laboratories, in 500 sq. ft. of space. Drs. Wondisford and Radovick will assist in the design of targeting constructs. The Core will be managed by Dr. Sidhaye, who will oversee the introduction of constructs into ES cells, identifying ES clones that have undergone homologous recombination along with the respective investigator's laboratory and preparation of cells for injection into blastocysts. Facilitating transport of genetically altered mice from JHU to UMD has been part of the Core's function. Alternatively, budgeted into the Core'are short-term housing costs at JHU for mice made for UMD Members, if their study protocol requires imaging or metabolic studies.